admin

A strong group of entrepreneurs ready and willing to innovate, fund and lead new bioscience companies is essential to the creation and sustainability of top-tier biohealth clusters. 

It is often referenced that the BioHealth Capital Region (BHCR) lacks a deep enough pool of qualified executive talent that is needed to sustain a larger cluster with more early-stage biotech startups. In fact, Ken Mills, CEO of REGENXBIO shared his feelings towards this void in leadership talent in a recent BBJ article, stating, “People who have experienced some success in the industry need to stay here and be the foundation for investing in new opportunities in biotech.”

Image: https://biobuzz.io

On September 17, the College of Health and Human Services kicked-off “Mason: Health Starts Here,” a first-of-its-kind transdisciplinary student cohort study to understand and improve the health of university students. Research will include a longitudinal study of a broad sample of young adults, specifically first-year Mason students, to capture the diversity of their experiences in college and how they affect their physical and behavioral health.

Image: https://chhs.gmu.edu

Alexandria has been at the vanguard of Seattle’s growing commercial life science ecosystem since entering the Seattle market in 1996 and is committed to developing a new, vibrant and connected campus to accelerate the discovery and delivery of novel innovations; create quality construction, life science and technology jobs; provide critical funds to address homelessness initiatives; activate the neighborhood; and help fulfill the company’s mission to advance human health

After a generation spent shaping the growth and development of biopharma clusters, Alexandria Real Estate Equities executive chairman and founder Joel Marcus recently spoke publicly about what will most likely drive the upcoming generation of hubs for biopharma and other emerging life sciences.

“If we focus for a moment on the next life science frontier, it’s pretty clear that the sheer scale of unmet medical needs for patients suffering from diseases of the brain is quite staggering, the cost to society enormous,” Marcus told analysts on Alexandria’s quarterly conference call July 30, according to a transcript published by Seeking Alpha. He cited the growing cost of treating dementia and Alzheimer’s disease, and the nation’s opioid epidemic.

AstraZeneca has successfully been striking deals at an industry-leading rate over the past five years, with a concerted surge in both out-licensing and in-licensing work, according to a new report,  Pharma Licensing Trends, 2014–18.

Analysts Datamonitor Healthcare put AstraZeneca comfortably ahead of other pharmaceutical firms, recognising the company as the most active dealmaker between 2014 and 2018, during which time it also signed the sector’s largest single deal.

Image: https://www.astrazeneca.com

Another day, another start-up making headlines about its transformational technology that’s set to disrupt a traditional sector, or its scientific breakthrough that will change the treatment standard for a horrible disease. “Sounds great!” you may be thinking. “Where do I invest?” Unfortunately, you can’t.

Let’s face it. Most of us aren’t able to invest in venture capital funds. The realm of private equity that fuels the growth of fledgling companies is reserved for endowments, pension plans, and high-net-worth, accredited investors. Is it possible for ordinary investors to gain exposure to this high-risk, high-reward arena? Yes, but only indirectly. 

NEW YORK (GenomeWeb) – The UK government said today that it has formed a strategic partnership with four pharmaceutical firms and a charity to provide £200 million ($247 million) to support sequencing the genomes of hundreds of thousands of participants in the UK Biobank.

The project aims to improve health through genetic research and to advance the prevention, diagnosis, and treatment of a variety of illnesses, including cancer, heart disease, diabetes, arthritis, dementia, and chronic kidney disease.

WASHINGTON, September 16, 2019 – Former U.S. Food and Drug Administration Commissioner Scott Gottlieb has been appointed to the FasterCures advisory board, executive director Tanisha Carino announced today.

Gottlieb has a unique vantage point into the biomedical research system, how breakthrough medical technologies are developed, and the promise new therapies can hold to cure disease and save lives, according to Carino.

As a member of the advisory board, Gottlieb will leverage decades of exp

Image: Scott Gottlieb – https://en.wikipedia.org/wiki/Scott_Gottlieb

Data hubs set up across the UK from October this year will enable cutting-edge research for health discoveries and aim to give patients across the UK faster access to pioneering treatments.

Pioneering data hubs that enable cutting-edge research for health discoveries and aim to give patients across the UK faster access to pioneering new treatments will be rolled out next month.

Led by Health Data Research UK, these hubs aim to improve the lives of people with debilitating conditions, and will link up different types of health data and make it more easily accessible and user-friendly for research, while maintaining strict controls around data privacy and consent.